MDBriefCase will be unavailable due to maintenance from Sunday, January 14 11PM to Monday, January 15 1AM ET.
Welcome
“The good physician treats the disease; the great physician treats the patient who has the disease.” –William Osler
Acromegaly is a rare disease with a wide range of symptoms, and many patients wait years before they are diagnosed and treatment is initiated. During this interval, serious complications can develop. Early diagnosis and treatment can lessen morbidity and mortality and can significantly improve patients’ quality of life.
Treatment of acromegaly may require the coordinated efforts of a team of specialists, including primary care physicians, endocrinologists, and neurosurgeons. Due to the variable nature of the disease, treatment must be individualized for each patient, based on that person’s symptoms. In general, the aims of treatment are to:
Most patients will require surgery to remove or debulk a pituitary tumour. Some will require medication or radiotherapy either in place of surgery or in combination with it.
Because surgery can result in rapid reduction in GH levels which, in turn, can alleviate symptoms, the primary form of treatment for the majority of acromegaly patients is transsphenoidal adenomectomy performed by a neurosurgeon who has experience with the procedure. However, success is closely correlated with the size and degree of the invasiveness of the tumour, along with the expertise of the surgeon.
When performed by experienced pituitary surgeons, microscopic or endoscopic transsphenoidal microsurgery results in endocrine remission of 90 percent for microadenomas and between 50 percent and 60 percent for macroadenomas. However, surgery may not be successful in resolving all symptoms (for example, headaches may persist).
Despite its rate of success, like any other surgery, it is not without risks. Complications from surgery may include bleeding, spinal fluid leak, meningitis, sodium and water imbalance, and hypopituitarism. Significant complications occur in about 5 percent of individuals.
In some patients, surgery improves hormone levels, but does not return them to normal, necessitating further treatment. Sometimes removal of the entire tumour may not be possible, resulting in GH levels that remain too high. In this situation, debulking of the tumour may be helpful.
Patients who are not candidates for surgery and those who need further treatment after surgery may respond to medical therapy. Using somatostatin analogs and GH-receptor antagonists is considered as principal therapy in these situations. Somatostatin receptor ligands, such as octreotide and lanreotide, have been used effectively for two decades. In selected patients, dopamine receptor agonists are another option.
Each of these medications has its own set of advantages and disadvantages, and specific risks and benefits must be carefully matched to individual patients.
Sometimes several different types of treatment are needed to achieve the desired results. In patients who fail to achieve biological control of their acromegaly after surgery and/or medical therapy, radiotherapy is considered to be the best curative method.
Radiotherapy is generally reserved for patients with tumours that have recurred following surgical removal and for patients with tumours that have persisted after surgery and have not responded to medical therapy.
There are two radiotherapy options:
Drawbacks of SRT are that it may not be available in all treatment locations and that it is not appropriate when there is a significant residual tumour burden or when the tumour is too close to the optic chiasm.
One advantage of radiotherapy is that it may lead to biochemical control, which can limit the need for lifelong medical therapy. However, it can take years for the full therapeutic effect to be achieved, and some patients may experience only a limited response. Therefore, medical therapy must be continued while awaiting the response from the radiotherapy. Periodic withdrawal of medical therapy for one to three months (depending on the specific drug treatment) for the assessment of GH and IGF-1 levels may be advisable.
In almost all cases of acromegaly, long-term treatment and monitoring are essential.
Diagnosis and treatment of acromegaly requires a multidisciplinary team for optimal disease management and improvement in patients’ quality of life. In addition, physicians should encourage better communication and collaboration between patients and their healthcare team.
Progress in both earlier diagnosis and in disease management have resulted in adequate hormonal control being achieved in the majority of cases, bringing the life expectancy of patients with acromegaly to a level comparable to that of the general population.
You can make a significant impact on your patients’ quality of life with the early diagnosis and prompt initiation of the right treatment. Learn more about acromegaly by taking a free course available at MDBriefCase:
Looking for the zebra: ACROMEGALY. An uncommon cause behind common conditions!
Join the MDBriefCase community today.
199 Bay Street #4000, Toronto,
ON M5L 1A9
In submitting your work (the “Work”) for potential posting on the MDBriefCase Healthcare Leadership Lab website (the “Website”), you (“You”) expressly agree to the following:
Review: MDBriefCase is pleased to consider the publication of Your Work on the Website. The suitability of the Work for posting shall be determined by MDBRiefCase at its sole discretion. Nothing herein shall obligate MDBriefcase to post or otherwise publish the Work, or the maintain its posting in future.
Editing; Identification: MDBriefcase shall have the right to edit the Work to conform to our standards of style, technological requirements, language usage, grammar and punctuation, provided that the meaning of the Work is not materially altered. If posted, You will be identified as the author of the Work, or co-author if applicable.
Grant of Rights: As a condition of publication and for no monetary compensation, You hereby grant to MDBriefCase the following rights to the Work in any and all media whether now existing or hereafter developed, including print and electronic/digital formats: (1) the exclusive right of first publication worldwide; (2) the perpetual non-exclusive worldwide right to publish, reproduce, distribute, sell, adapt, perform, display, sublicense, and create derivative works, alone or in conjunction with other materials; (3) the perpetual non-exclusive worldwide right to use the Work, or any part thereof, in any other publication produced by MDBriefCase and/or on MDBriefCase’s website; and (4) the perpetual non-exclusive worldwide right to use the Work to promote and publicize MDBriefCase or its publications. The grant of rights survives termination or expiration of this Agreement.
Warranty: You warrant that the Work is original with You and that it is not subject to any third party copyright; that You have authority to grant the rights in this Agreement; that publication of the Work will not libel anyone or infringe on or invade the rights of others; that You have full power and authority to enter into this Agreement; that the Work has not been published elsewhere in whole or in part; and that You have obtained permission from the copyright owner consistent with this Agreement for any third party copyrighted material in the Work. This warranty survives termination or expiration of this Agreement.
Thank you for your interest in writing an article for the MDBriefCase Healthcare Leadership Lab website.
The Healthcare Leadership Lab welcomes submissions on all topics relevant to leaders in healthcare. Our topics include Leading in Healthcare, Leadership Lessons from COVID-19 and others. We prioritize stories that provide leadership advice to executives and managers in healthcare companies, offer actionable strategies for executing successful projects, and provide interesting angles on current healthcare topics. Submissions must be original work of the authors and unpublished. When submitting, authors represent that they have included no material that is in violation of the rights of any other person or entity.
Articles must be educational and non-promotional. If they mention the author’s company or any of the company’s products or services by name within the text, such mention should be very limited and used for reference only, not for promotion. (For example, an author might cite a survey conducted by his company but not describe his company’s product as a solution to a business problem.) Articles will be edited for clarity, style and brevity. The final headline is determined by the editor.
Guest articles for the MDBriefCase Healthcare Leadership Lab may run between 500 and 1000 words.
MDBriefCase reserves the right to accept or reject any submission and the right to condition acceptance upon revision of material to conform to its criteria.
There is no payment for contributed articles. However, MDBriefCase will give the author a byline. Authors are invited to link to the article on personal websites, corporate websites and social media platforms.
Each author understands and agrees that any submission accepted for posting is provided subject to MDBriefCase’s Author Agreement.
